Q2 2023 Earnings Presentation

Track record of strong financial returns for shareholders (Financial data as of December 31, 2022) Revenue ($B) 11% CAGR $3.8 $2.2 LTM 2Q18 LTM 1Q23 Non-GAAP Operating Income ($M) Non-GAAP EPS $548 15% CAGR $1,121 LTM 2Q18 LTM 2Q23 $3.14 14% CAGR $5.98 LTM 2Q18 LTM 2Q23 Total shareholder return, TSR (NYSE shares as of 12/31/2022): 1-yr (19)% | 3-yr 37% | 5-yr 159% NOTE: See reconciliation to GAAP in Appendix 102023 ResMed | Q2 2023 Earnings Presentation - Jan. 26, 2023 ResMed

View entire presentation